
The £8 Boots buy that's a dupe of posh £49 Kerastase – it makes your hair grow thick and my locks are proof it works
TikTok hair expert Sophia, aka Sofia Hair Health, has revealed an £8.49 miracle product from Asos that could be giving posh £49 Kerastase Genesis a run for its money.
3
3
Sofia, a 24-year-old hair researcher from London, isn't just another influencer flogging the latest fad. She's lived it.
At just 21, she started losing her hair, not just a few strands here and there, but actual bald patches that left her confidence in tatters.
'I'd wake up and see more scalp than hair,' she revealed.
'Then I spotted actual bald patches. I felt like I was disappearing.'
Eventually diagnosed with androgenic alopecia, a genetic condition that causes thinning hair, usually in older women, Sofia was told there was no cure, only ongoing treatments that might help slow it down.
But instead of giving up, she threw herself into studying hair biology and researching every treatment under the sun.
Now, three years on, her glossy, thick locks are proof her efforts paid off.
The hair expert has now put fans onto a humble bottle of L'Oréal Elvive Hair Growth Serum with Aminexil, currently available at Asos for just £8.49.
Buy it here
At Boots, this would set you back £17.
She claims this product has "changed the game".
Sophia said: 'It's got the same powerhouse ingredient as the £49 Kerastase Genesis, aminexil, which helps loosen collagen around the hair follicle and boosts growth.'
How do get the perfect summer glow up with Aldi's latest middle aisle beauty buys including a £4.99 serum that'll revitalise dull skin AND smells amazing
Both Elvive and Kerastase are owned by beauty giant L'Oréal, and according to Sofia, they share more than just a parent company.
She points out that the product also has other key ingredients you'd find in Kerastase, like caffeine and niacinamide, which are both great for stimulating growth and improving scalp health.
But here's where it gets really interesting, L'Oréal reportedly disclosed the concentration of aminexil in Elvive's serum as 1.5%.
In contrast, they've kept quiet about the concentration in the pricier Kerastase Genesis.
Sophia warns this is a red flag and that if Elvive is cheaper and tells you exactly what you're getting, then there's no need to fork out on a £49 "just for a fancy bottle".
Since using the key ingredient in this product her hair has gone from 'lifeless and patchy' to 'thicker, stronger and full of volume.
And judging by the hundreds of glowing comments on her videos, not to mention her jaw-dropping before and after pics, her followers are lapping it up.
Sophia said "you're not missing out on results", just on "the expensive packaging.'
It looks like this hair guru has found our new holy grail and it won't cost half your paycheck.
It's important to remember the prices mentioned reflect the rates at the time of writing.
As prices can change over time, we recommend double-checking before placing an order.
Hair re-growth FAQs
Anabel Kingsley, Consultant Trichologist and Brand President at Philip Kingsley spoke exclusively to Fabulous.
How long does it take for hair to grow back?
Hair grows, on average, half an inch a month. You cannot speed this up.
Do rosemary oil and scalp massages work?
Oils do not promote hair growth. In terms of rosemary oil, the current trend stems from one small study carried out on 50 men in 2015. No women were involved, and the study compared the effects of 2 per cent minoxidil to Rosemary oil. 2 per cent minoxidil doesn't do much for
male pattern hair loss anyway, so the results were not very impressive. Oils do serve a purpose in conditioning hair treatments though. They help add shine and smooth the hair cuticle to lock-in moisture and improve combability. Scalp massages alone won't cure hair loss, but it can help relax you, aid in lymphatic drainage, exfoliate and help topicals penetrate.
Are there any products or foods/vitamins you recommend someone using or eating to help with hair regrowth?
To support healthy hair regrowth, if you are experiencing hair thinning we'd recommend our Density Preserving Scalp Drops clinically proven to help slow hair loss with continued daily use within three months.
Telogen effluvium (hair shedding) due to nutritional deficiencies can often be simply treated with changes to your diet, and nutritional supplements such as our specially formulated Density Healthy Hair Complex and Density Amino Acid Booster.
Iron and Ferritin (stored iron) in red meat, dried apricots and dark, leafy greens. Vitamin B12 in animal products and fortified plant-based foods. Protein from oily fish, lean meat, cottage cheese, tofu, nuts, chickpeas, and beans.
However, there may be an underlying cause for their hair loss and rather than this being masked by using an off-the-shelf product, they should be encouraged to seek the advice of a specialist such as a Trichologist.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
27 minutes ago
- The Independent
Breast cancer breakthrough as new test could revolutionise treatment
A new test for breast cancer patients has been developed which can predict whether or not their cancer is likely to return just two weeks after they start treatment. Experts said thousands of breast cancer patients could be spared unnecessary treatment as a result. The new test has been devised by scientists to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive – which accounts for around 200,000 cases of cancer each year around the globe. Writing in the journal eBioMedicine, experts said the test means that some patients will be able to 'de-escalate' their treatment while it could also help identify those who need 'more intensive therapeutic strategies'. The test, which was developed by scientists at The Institute for Cancer Research, London, correctly identifies the 6% of patients at highest risk of relapse. Researchers analysed tumour samples from 213 patients. They found that two weeks of hormone therapy changes the characteristics of some tumours, causing them to shift their subtype. The patients with the highest risk of cancer returning had a type of tumour called Luminal B that did not change after this short-term hormone therapy. Experts said these patients will require more intensive treatment. They said the findings highlight the benefit of two weeks of hormone therapy before surgery to help guide doctors' decision making. Corresponding author of the study, Dr Maggie Cheang, from The Institute of Cancer Research, London, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'


Daily Mail
28 minutes ago
- Daily Mail
New test taken two weeks after starting treatment for breast cancer can tell if the disease is likely to return
A new test taken two weeks after starting treatment for breast cancer can tell if the disease is likely to return. The breakthrough could spare thousands of patients unnecessary therapy while allowing others to receive more intensive care sooner. Researchers at The Institute of Cancer Research, London, found taking hormone drugs for a fortnight changed the characteristics of some tumours, causing them to shift their subtype. Patients with the highest risk of relapsing had a type of tumour called Luminal B that did not change after this short-term therapy. These cases, accounting for 6 per cent of the 213 patients studied, require more intensive treatment that others could avoid. Experts say the findings, published in the journal eBioMedicine, highlight the benefit of taking hormone therapy before surgery to help guide doctors' decision making. The new test works for a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive, of which there are around 200,000 cases globally each year. Study author Dr Maggie Cheang, from the ICR, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. 'In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of the IRC, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at charity Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'


BBC News
28 minutes ago
- BBC News
RSV vaccine to be offered to premature babies in Northern Ireland
A vaccination programme to tackle respiratory syncytial virus (RSV) is to be extended to cover premature babies born in Northern Ireland.A long-acting injection is to be offered for eligible children from this is a common, but highly infectious, respiratory virus that affects the breathing system, particularly in young children and older infects 90% of children by the age of two and is one of the leading causes of hospitalisation in the first year of life. An RSV vaccine has been available to pregnant women in Northern Ireland since last September and is offered from 28 weeks of new programme will cover those infants born very prematurely and too early to benefit from the RSV vaccination given to their single Nirsevimab injection offers about 80% protection and replaces Palivizumab, which gives 55% protection and is administered up to five follows advice from the Joint Committee on Vaccination and Immunisation. Chief Medical Officer Sir Michael McBride said: "Vaccinations have been extremely effective in eradicating diseases and protecting children and other vulnerable groups from serious illness and death."Worryingly, we are now seeing a decline in the uptake of childhood immunisations."Vaccinations offer children the very best start in life. Quite simply, if children aren't vaccinated, they're not protected."Health Minister Mike Nesbitt said the new vaccine would strengthen winter preparedness in the health service and reduce pressures on GPs, emergency departments and hospital admissions.